Table.

Demographic and clinical features of Parkinson patients with and without pain

	PD with Pain (n=269)	PD without Pain (n=632)	p value	Multivariate analysis
	No. (%)	No. (%)		OR (95%CI)	p value
Age at enrollment (vs. <65 years)	128 (47.6)	274 (43.4)	0.37	Reference	0.46
65–74 years	92 (34.2)	220 (34.8)		0.88 (0.63–1.23)
≥75 years	49 (18.2)	135 (21.8)		0.78 (0.52–1.17)
Male, n (%)	151 (56.1)	411 (65.0)	0.01	0.74 (0.54–1.01)	0.06
Education, years (vs 0–6)	54 (20.1)	150 (23.7)	0.48	Reference	0.13
7–12	125 (46.5)	277 (43.8)		1.39 (0.93–2.09)
≥13	90 (33.5)	205 (32.4)		1.54 (1.00–2.37)
PD duration, years (vs <5)	151 (56.1)	400 (63.3)	0.10	Reference	0.51
5–9	82 (30.5)	153 (24.2)		1.17 (0.82–1.66)
≥10	36 (13.4)	79 (12.5)		0.89 (0.55–1.45)
HY stage (vs stage I)	44 (20.4)	129 (16.4)	0.01
stage II	159 (63.5)	401 (59.1)
stage III	66 (16.1)	102 (24.5)
L-dopa use	38 (14.1)	126 (19.9)	0.04	Reference	0.12
Yes	231 (85.9)	506 (80.1)		1.40 (0.91–2.15)
Motor fluctuation (vs no)	218 (81.0)	544 (86.4)	0.26	Reference	0.75
Yes	51 (19.0)	86 (13.6)		1.08 (0.69–1.68)
Dyskinesias (vs no)	135 (87.4)	603 (95.4)	<0.001	Reference	<0.001
Yes	34 (12.6)	29 (4.6)		2.66 (1.50–4.73)
Depression (vs no)	44 (79.2)	46 (91.5)	<0.001	Reference	<.0001
Yes	56 (20.8)	54 (8.5)		2.88 (1.87–4.44)

HY stage was not included in the multivariate analysis due to colinearity. When HY stage, but not PD duration, was included in the multivariate logistic regression model, the OR comparing higher HY stage with stage I was 1.11 (95%CI 0.74–1.66) for stage II, 1.59 (95%CI 0.95–2.68) for stage III